(TSX:EIT-UN),(TSX:EIT.UN),(TSX:EIT-PA),(TSX:EIT-PB), CALGARY, Alberta, Nov. 06, 2025 (GLOBE NEWSWIRE) — Canoe EIT Income Fund (the “Fund”) (TSX – EIT.UN) announces the November 2025 monthly distribution of $0.10 per unit. Additionally, the Fund announces a quarterly distribution for preferred units. Cumulative Redeemable Series 1 (EIT.PR.A) and Series 2 Preferred (EIT.PR.B) unitholders will receive a distribution of $0.30 […]

(NASDAQ:IPGP), MARLBOROUGH, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — IPG Photonics today announced the grand opening of its new office and manufacturing facility in Huntsville, Alabama. This location in Redstone Gateway will be the headquarters of the newly created IPG Defense business and dedicated to the development and production of laser defense solutions for both

(NASDAQ:GROW), San Antonio, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (Nasdaq: GROW) will host a webcast on Thursday, November 13, at 7:30 a.m. Central time to discuss the company's results for fiscal year 2025. ­Financial data for the fiscal year will be released prior to the webcast. Frank Holmes, Chief Executive

(NASDAQ:ORIC), SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the publication of a peer-reviewed research paper in Cancer Research, a journal of the American Association for Cancer Research.

(Paris:IVA), Daix (France), New York City (New York, United States), November 6, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company“), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the availability of the preparatory documents for the Combined

(Paris:IVA), Article R. 22-10-23 of the French Commercial Code Market : Euronext ParisISIN code / Mnemo : FR0013233012 / IVAWeb site : www.inventivapharma.com Date Number of Shares Outstanding Total voting rights, gross (1) Total voting rights, net (2) October 20th, 2025 145 951 274 158 653 570 158 594 019 (1) The total number of

FDCTech, Inc. Completes Acquisition of Alchemy International Ltd., a Licensed Securities Dealer in Seychelles GlobeNewswire November 06, 2025 Strategic Expansion Bolsters Company's Global Regulatory Footprint and Institutional Brokerage Capabilities Irvine, CA, Nov. 06, 2025 (GLOBE NEWSWIRE) — FDCTech, Inc. (“FDC” or the “Company,” PINK: FDCT), a fintech-infrastructure provider, today announced it has finalized the acquisition

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates GlobeNewswire November 06, 2025 Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-z Presenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term Phase 1 clinical data for nex-z for ATTRv-PN

IREN Reports Q1 FY26 Results GlobeNewswire November 06, 2025 Secured $9.7bn AI Cloud Contract with Microsoft Targeting $3.4bn AI Cloud ARR by End of 2026, Expansion to 140k GPUs 1 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (“IREN” or “the Company”) today reported its financial results for the three months

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire November 06, 2025 Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improved safety